title: The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Algorithm for Generalized Anxiety Disorder.
abstract: This revision of previous algorithms for the pharmacotherapy of generalized anxiety disorder was developed by the Psychopharmacology Algorithm Project at the Harvard South Shore Program. Algorithms from 1999 and 2010 and associated references were reevaluated. Newer studies and reviews published from 2008-14 were obtained from PubMed and analyzed with a focus on their potential to justify changes in the recommendations. Exceptions to the main algorithm for special patient populations, such as women of childbearing potential, pregnant women, the elderly, and those with common medical and psychiatric comorbidities, were considered. Selective serotonin reuptake inhibitors (SSRIs) are still the basic first-line medication. Early alternatives include duloxetine, buspirone, hydroxyzine, pregabalin, or bupropion, in that order. If response is inadequate, then the second recommendation is to try a different SSRI. Additional alternatives now include benzodiazepines, venlafaxine, kava, and agomelatine. If the response to the second SSRI is unsatisfactory, then the recommendation is to try a serotonin-norepinephrine reuptake inhibitor (SNRI). Other alternatives to SSRIs and SNRIs for treatment-resistant or treatment-intolerant patients include tricyclic antidepressants, second-generation antipsychotics, and valproate. This revision of the GAD algorithm responds to issues raised by new treatments under development (such as pregabalin) and organizes the evidence systematically for practical clinical application.
authors.affiliation: From Harvard Medical School; Boston Children's Hospital, Boston, MA (Dr. Abejuela); VA Boston Healthcare System, Brockton Division, Brockton, MA (Dr. Osser).
authors.forename: Harmony Raylen
authors.initials: HR
authors.lastname: Abejuela
authors.forename: David N
authors.initials: DN
authors.lastname: Osser
mesh_terms: D000465:Algorithms; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D004357:Drug Synergism; D006801:Humans; D018377:Neurotransmitter Agents / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
chemical_list: D014151:Anti-Anxiety Agents; D018377:Neurotransmitter Agents